RegWardenFDA facility compliance records
Facility

WONDFO USA CO., LTD.

1 recall(s) on record — most severe on record: Class II.

Activity by year

FDA actions on record by year2018: 1 inspections; 2024: 1 recalls201712018201920202021202220231202420252026
  • Recalls (1)
  • Inspections (1)

Devices registered here (1)

  • Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings
    Product code QVF (opens in a new tab) · Class II · Microbiology · 21 CFR 866.3982

Recalls & enforcement

  • Class IIOngoing2024-04-22
    Wondfo USA has identified unauthorized distribution of the Preview Strep A Test Kit. Unauthorized distribution of this device would include sales and distribution of this test for at-home use, non-prescription use, over-the-counter use, or direct-to-consumer customers.

FDA inspections (1)

  • VAI2018-05-11
    Voluntary Action Indicated · Compliance: Devices; Postmarket Assurance: Devices · citations posted

Source: U.S. FDA Inspections Dashboard (opens in a new tab) (device inspection classifications, 2016–present). Data as of 2026-10-06. The dashboard profile can take several seconds to load.

Related

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)

Cite this record

RegWarden. “WONDFO USA CO., LTD. (FEI 3007606081) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/3007606081-wondfo-usa-co-ltd/

Not open yet

Alerts for WONDFO USA CO., LTD.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.